New Nanosized Biocompatible MR Contrast Agents Based on Lysine-Dendri-Graft Macromolecules
- 17 March 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 21 (5), 955-960
- https://doi.org/10.1021/bc9005442
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Drug nanocarriers and functional nanoparticles: applications in cancer therapy.Current Drug Delivery, 2009
- Dendrimers at WorkScience, 2006
- Nano-sized MRI contrast agents with dendrimer coresAdvanced Drug Delivery Reviews, 2005
- Extracellular biodegradable macromolecular gadolinium(III) complexes for MRIMagnetic Resonance in Medicine, 2003
- Novel intravascular macromolecular MRI contrast agent with generation-4 polyamidoamine dendrimer core: accelerated renal excretion with coinjection of lysine.Magnetic Resonance in Medicine, 2001
- Synthesis and relaxometry of high-generation (G = 5, 7, 9, and 10) PAMAM dendrimer-DOTA-gadolinium chelatesJournal of Magnetic Resonance Imaging, 1999
- L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment.1996
- Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives.1995
- Dendrimer‐based metal chelates: A new class of magnetic resonance imaging contrast agentsMagnetic Resonance in Medicine, 1994
- Permselectivity of the glomerular capillary wall to macromolecules. II. Experimental studies in rats using neutral dextranBiophysical Journal, 1975